Breaking News Instant updates and real-time market news.

HALO

Halozyme

$16.96

0.04 (0.24%)

, ARGX

Argenx

$146.76

2.96 (2.06%)

08:08
07/17/19
07/17
08:08
07/17/19
08:08

Halozyme to receive $5M milestone payment from Argenx

Halozyme (HALO) announced that Argenx (ARGX) has dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of efgartigimod, using Halozyme's proprietary Enhanze drug delivery technology. Initiation of this study triggers a $5M milestone payment to Halozyme during the current quarter under the global collaboration and license agreement between the two companies.

HALO

Halozyme

$16.96

0.04 (0.24%)

ARGX

Argenx

$146.76

2.96 (2.06%)

  • 30

    Jul

  • 09

    Sep

HALO Halozyme
$16.96

0.04 (0.24%)

11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.
07/01/19
CANT
07/01/19
NO CHANGE
Target $27
CANT
Overweight
Halozyme price target raised to $27 from $24 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Halozyme Therapeutics to $27 from $24 after including potential future royalty revenues from Enhanze-enhanced drugs developed by partner companies. The analyst continues to view the approval and launch of the Enhanze-based products as "fueling sustainable revenue growth" through 2027, with the Darzalex program as the near-term driver. He sees "notable potential" share upside "almost irrespective" of the outcome of the HALO-301 Phase trial in pancreatic cancer later in 2019. Duncan reiterates an Overweight rating on Halozyme.
ARGX Argenx
$146.76

2.96 (2.06%)

03/01/19
WEDB
03/01/19
NO CHANGE
Target $131
WEDB
Outperform
Argenx removed from Best Ideas List at Wedbush
Wedbush removed Argenx from the Best Ideas List on valuation as the stock is up about 66% vs. the S&P 500 since it was added to the list in September. The firm remains positive on the name and sees several value-adding events in 2019, but does not see any major share catalysts for the year.
03/18/19
BTIG
03/18/19
INITIATION
BTIG
Neutral
Momenta initiated with a Neutral at BTIG
BTIG analyst Thomas Shrader initiated Momenta (MNTA) with a Neutral rating, saying that while he is positive on the company's IVIg-focused re-positioning, the stock is not cheap and the proof-of-concept for its analytical focus is at least a year away. The analyst also states that the bulk of his modeled value for the company comes from its pipeline development in treating maternal-fetal autoimmune disease, noting that competition in the space is "fierce" and that Momenta is "significantly behind Argenx (ARGX) in the development of FcRn blockers.
05/23/19
PIPR
05/23/19
NO CHANGE
Target $182
PIPR
Overweight
Argenx price target raised to $182 from $161 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Argenx to $182 from $161 after the company debuted two first-in-class antibodies, ARGX-117 and ARGX-118. ARGX-117 is a C2 inhibitor with broad applicability in complement-mediated diseases including neuromuscular and kidney indications, while ARGX-117 is engineered with NHance technology to enable a "sweeping" mechanism that prevents lysosomal degradation and extends pharmacodynamic effect, Tenthoff tells investors in a research note. The analyst believes Argenx is competitively positioned from FcRn competitors with development of both intravenous and subcutaneous efgartigimod formulations. He reiterates an Overweight rating on the shares.
06/27/19
BARD
06/27/19
INITIATION
Target $170
BARD
Outperform
Argenx initiated with an Outperform at Baird
Baird analyst Michael Ulz initiated Argenx with a Buy and $170 price target telling investors it has a differentiated antibody platform and has built a robust pipeline. Ulz said efgartigimod has demonstrated a best-in-class profile with potential across multiple autoimmune diseases, and early data for cusatuzumab in AML looks promising. This combined with validating partnerships and multiple catalysts over the next two years support continued upside, the analyst wrote in a note to investors.

TODAY'S FREE FLY STORIES

AVAV

AeroVironment

$57.14

0.02 (0.04%)

05:00
10/16/19
10/16
05:00
10/16/19
05:00
Upgrade
AeroVironment rating change  »

AeroVironment upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$17.65

0.2 (1.15%)

04:57
10/16/19
10/16
04:57
10/16/19
04:57
Upgrade
Pure Storage rating change  »

Pure Storage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

BOALY

Boral

$0.00

(0.00%)

04:56
10/16/19
10/16
04:56
10/16/19
04:56
Downgrade
Boral rating change  »

Boral downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Wedbush technology analyst to hold an analyst/industry webcast »

Technology Analyst…

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Wedbush technology analyst to hold an analyst/industry webcast »

Technology Analyst…

JCOM

j2 Global

$96.34

0.47 (0.49%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
j2 Global management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 01

    Nov

  • 19

    Nov

AUY

Yamana Gold

$3.19

-0.1 (-3.04%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Yamana Gold management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 25

    Oct

SCS

Steelcase

$18.15

0.29 (1.62%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Steelcase management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TRVI

Trevi Therapeutics

$4.00

-0.55 (-12.09%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Trevi Therapeutics management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

CHWY

Chewy

$26.80

1.03 (4.00%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Chewy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

MREO

Mereo BioPharma

$3.58

0.08 (2.29%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Mereo BioPharma management to meet with SVB Leerink »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
BTIG to hold a forum »

Energy & Shipping…

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
FBN Securities cannabis analysts to hold a breakfast meeting »

Analysts host Chairman…

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Media & Entertainment…

NXTC

NextCure

$26.93

-0.175 (-0.65%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
NextCure management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

PIRS

Pieris Pharmaceuticals

$3.22

0.01 (0.31%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Pieris Pharmaceuticals management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 31

    Oct

FLGT

Fulgent Genetics

$11.14

0.09 (0.81%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Fulgent Genetics management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 04

    Nov

ISEE

IVERIC bio

$0.99

-0.0016 (-0.16%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
IVERIC bio management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TORC

resTORbio

$6.89

-0.09 (-1.29%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
resTORbio management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

04:55
10/16/19
10/16
04:55
10/16/19
04:55
General news
Breaking General news story  »

Chicago Federal Reserve…

04:55
10/16/19
10/16
04:55
10/16/19
04:55
General news
Breaking General news story  »

Week of 10/11 MBA…

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Wedbush enterprise software analysts to hold an advisor luncheon »

Enterprise Software…

TTGT

TechTarget

$22.87

0.47 (2.10%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.87

0.47 (2.10%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$53.09

0.88 (1.69%)

HPE

HP Enterprise

$15.15

0.21 (1.41%)

HLF

Herbalife Nutrition

$38.08

-0.67 (-1.73%)

FORR

Forrester

$33.93

1.325 (4.06%)

CSCO

Cisco

$46.37

0.33 (0.72%)

CVLT

Commvault

$45.22

-0.24 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 29

    Oct

  • 29

    Oct

  • 01

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

CKPT

Checkpoint Therapeutics

$2.10

0.08 (3.96%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Checkpoint Therapeutics management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

RGSE

RGS Energy

$0.00

(0.00%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
RGS Energy to host business news update conference call »

Business Update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.